The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Studies Addressing Rare Neurodegenerative Diseases including ALS," aimed at supporting research that advances the development of medical products for the prevention, diagnosis, treatment, or cure of ALS and other rare neurodegenerative diseases in both adults and children. This funding opportunity seeks to address critical knowledge gaps in the field and is expected to have a significant impact on the understanding and management of these diseases, thereby informing future product development. The FDA anticipates awarding approximately 10 grants under this initiative, with no cost-sharing or matching requirements, and the fiscal year for this funding is 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.